title: Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27.
abstract: Retinoic acid (RA) treatment of embryonal carcinoma cell line NTERA-2 clone D1 (NT2/D1) induces growth arrest and terminal differentiation along the neuronal pathway. In the present study, we provide a functional link between RA and p27 function in the control of neuronal differentiation in NT2/D1 cells. We report that RA enhances p27 expression, which results in increased association with cyclin E/cyclin-dependent kinase 2 complexes and suppression of their activity; however, antisense clones, which have greatly reduced RA-dependent p27 inducibility (NT2-p27AS), continue to synthesize DNA and are unable to differentiate properly in response to RA as determined by lack of neurite outgrowth and by the failure to modify surface antigens. As to the mechanism involved in RA-dependent p27 upregulation, our data support the concept that RA reduces p27 protein degradation through the ubiquitin/proteasome-dependent pathway. Taken together, these findings demonstrate that in embryonal carcinoma cells, p27 expression is required for growth arrest and proper neuronal differentiation.
authors.affiliation: Servizio Oncologia Sperimentale E, Istituto Nazionale Tumori, Naples, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Baldassarre
authors.forename: A
authors.initials: A
authors.lastname: Boccia
authors.forename: P
authors.initials: P
authors.lastname: Bruni
authors.forename: C
authors.initials: C
authors.lastname: Sandomenico
authors.forename: M V
authors.initials: MV
authors.lastname: Barone
authors.forename: S
authors.initials: S
authors.lastname: Pepe
authors.forename: T
authors.initials: T
authors.lastname: Angrisano
authors.forename: B
authors.initials: B
authors.lastname: Belletti
authors.forename: M L
authors.initials: ML
authors.lastname: Motti
authors.forename: A
authors.initials: A
authors.lastname: Fusco
authors.forename: G
authors.initials: G
authors.lastname: Viglietto
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018236:Carcinoma, Embryonal / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D018797:Cell Cycle Proteins; D002454:Cell Differentiation / Q000187:drug effects; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D003546:Cysteine Endopeptidases / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008869:Microtubule-Associated Proteins / Q000235:genetics / Q000378:metabolism; D009097:Multienzyme Complexes / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000378:metabolism / Q000473:pathology*; D046988:Proteasome Endopeptidase Complex; D014212:Tretinoin / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins
chemical_list: D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D008869:Microtubule-Associated Proteins; D009097:Multienzyme Complexes; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D014212:Tretinoin; D018844:Cyclin-Dependent Kinases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex